* 中国生物科技公司--开拓药业9939.HK周四早盘高开2.8%，随后涨幅扩大至7.1%。
* 该公司此前公告称，自主研发、潜在同类首创的KX-826酊1.0%治疗中国成年男性雄激素脱发的关键性临床试验II期阶段已达到主要研究终点，在每日两次治疗24周后，低剂量组的目标区域非毳毛数量较基线增加22.39根/平方厘米，高剂量组的目标区域非毳毛数量较基线增加21.87根/平方厘米，安慰剂组则较基线增加8.73根/平方厘米。
* 开拓药业今年迄今暴涨173.2%，同期恒生指数.HSI大幅上扬27.6%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升1.2%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 屈桂娟)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.